The role of probiotics and prebiotics in inducing gut immunity

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Vieira, Angélica T ^a   Teixeira, Mauro M ^a   Martins, Flaviano S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Gut inflammation; Microbiota; Mucosal immunity; Prebiotics; Probiotics

Indexed keywords

ACTIMEL; ACTIVIA; CULTURELLE; ENTEROGERMINA; FLORASTOR; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; GUAR GUM; INULIN; MIYARISAN; MUTAFLOR; PECTIN; PREBIOTIC AGENT; PROBIO TEC; PROBIOTIC AGENT; SELENIUM; SYMBIOTIC AGENT; ULTRA LEVURE; UNCLASSIFIED DRUG; VSL3; YAKULT;

BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLOSTRIDIUM BUTYRICUM; CORALLINE ALGA; DIET; ESCHERICHIA COLI; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INTESTINE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; LITHOTHAMNIUM MUELLERI; MICROFLORA; NONHUMAN; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS SALIVARIUS;

EID: 84892162680     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00445     Document Type: Review

References (198)

1. Pabst R, Russell MW, Brandtzaeg P. Tissue distribution of lymphocytes and plasma cells and the role of the gut. Trends Immunol (2008) 29:206-8. doi:10.1016/j.it.2008.02.006.
2. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol (2010) 10:159-69. doi:10.1038/nri2710.
3. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science (2012) 336:1268-73. doi:10.1126/science.1223490.
4. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 464:59-65. doi:10.1038/nature08821.
5. Louis P, O'Byrne CP. Life in the gut: microbial responses to stress in the gastrointestinal tract. Sci Prog (2010) 93:7-36. doi:10.3184/003685009X12605525292307.
6. Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol (2013) 14:685-90. doi:10.1038/ni.2608ni.2608.
7. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol (2008) 8:411-20. doi:10.1038/nri2316.
8. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A (2011) 108(Suppl 1):4607-14. doi:10.1073/pnas.10000921071000092107.
9. Duerr CU, Hornef MW. The mammalian intestinal epithelium as integral player in the establishment and maintenance of host-microbial homeostasis. Semin Immunol (2012) 24:25-35. doi:10.1016/j.smim.2011.11.002.
10. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 482:179-85. doi:10.1038/nature10809nature10809.
11. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med (2013) 5:193ra191. doi:10.1126/scitranslmed.30064385/193/193ra91.
12. Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 339:548-54. doi:10.1126/science.1229000.
13. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol (2009) 587:4153-8. doi:10.1113/jphysiol.2009.174136.
14. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature (2009) 457:480-4. doi:10.1038/nature07540.
15. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, De Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 368:407-15. doi:10.1056/NEJMoa1205037.
16. Blottiere HM, De Vos WM, Ehrlich SD, Dore J. Human intestinal metagenomics: state of the art and future. Curr Opin Microbiol (2013) 16:232-9. doi:10.1016/j.mib.2013.06.006S1369-5.
17. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 500:541-6. doi:10.1038/nature12506.
18. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B, Lodinova-Zadnikova R, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett (2004) 93:97-108. doi:10.1016/j.imlet.2004.02.005.
19. Kamada N, Nunez G. Role of the gut microbiota in the development and function of lymphoid cells. J Immunol (2013) 190:1389-95. doi:10.4049/jimmunol.1203100190/4/1389.
20. Gordon HA. Morphological and physiological characterization of germfree life. Ann N Y Acad Sci (1959) 78:208-20. doi:10.1111/j.1749-6632.1959.tb53104.x.
21. Glaister JR. Factors affecting the lymphoid cells in the small intestinal epithelium of the mouse. Int Arch Allergy Appl Immunol (1973) 45:719-30. doi:10.1159/000231071.
22. Cebra JJ, Periwal SB, Lee G, Lee F, Shroff KE. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol (1998) 6:13-8. doi:10.1155/1998/68382.
23. Wagner M, Wostmann BS. Serum protein fractions and antibody studies in gnotobiotic animals reared germfree or monocontaminated. Ann N Y Acad Sci (1961) 94:210-7. doi:10.1111/j.1749-6632.1961.tb35542.x.
24. Sell S, Fahey JL. Relationship between gamma-globulin metabolism and low serum gamma-globulin in germfree mice. J Immunol (1964) 93:81-7.
25. Moreau MC, Ducluzeau R, Guy-Grand D, Muller MC. Increase in the population of duodenal immunoglobulin A plasmocytes in axenic mice associated with different living or dead bacterial strains of intestinal origin. Infect Immun (1978) 21:532-9.
26. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut (2003) 52:237-42. doi:10.1136/gut.52.2.237.
27. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut (2012) 61:997-1006. doi:10.1136/gutjnl-2011-301501.
28. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol (2013) 13:321-35. doi:10.1038/nri3430.
29. Simren M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2013) 62:159-76. doi:10.1136/gutjnl-2012-302167.
30. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol (2011) 128(646-652):e641-5. doi:10.1016/j.jaci.2011.04.060.
31. Kalliomaki M, Isolauri E. Pandemic of atopic diseases-a lack of microbial exposure in early infancy? Curr Drug Targets Infect Disord (2002) 2:193-9. doi:10.2174/1568005023342452.
32. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol (2002) 109:119-21. doi:10.1067/mai.2002.120273.
33. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol (2007) 119:192-8. doi:10.1016/j.jaci.2006.09.009.
34. Barker DJ. The origins of the developmental origins theory. J Intern Med (2007) 261:412-7. doi:10.1111/j.1365-2796.2007.01809.x.
35. Boyle RJ, Mah LJ, Chen A, Kivivuori S, Robins-Browne RM, Tang ML. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin Exp Allergy (2008) 38:1882-90. doi:10.1111/j.1365-2222.2008.03100.x.
36. Laitinen K, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr (2009) 101:1679-87. doi:10.1017/S0007114508111461.
37. Podolsky S. Cultural divergence: Elie Metchnikoff's Bacillus bulgaricus therapy and his underlying concept of health. Bull Hist Med (1998) 72:1-27. doi:10.1353/bhm.1998.0056.
38. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 118:229-41. doi:10.1016/j.cell.2004.07.002.
39. Eberl G, Boneca IG. Bacteria and MAMP-induced morphogenesis of the immune system. Curr Opin Immunol (2010) 22:448-54. doi:10.1016/j.coi.2010.06.002.
40. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol (2010) 10:131-44. doi:10.1038/nri2707nri2707.
41. Yeretssian G. Effector functions of NLRs in the intestine: innate sensing, cell death, and disease. Immunol Res (2012) 54:25-36. doi:10.1007/s12026-012-8317-3.
42. Lavelle EC, Murphy C, O'Neill LA, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol (2010) 3:17-28. doi:10.1038/mi.2009.124.
43. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature (2012) 489:231-41. doi:10.1038/nature11551.
44. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev (2004) 2:CD003048. doi:10.1002/14651858.CD003048.pub2.
45. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol (2011) 45(Suppl):S149-53. doi:10.1097/MCG.0b013e3182257e98.
46. Szajewska H, Wanke M, Patro B. Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Aliment Pharmacol Ther (2011) 34:1079-87. doi:10.1111/j.1365-2036.2011.04837.x.
47. Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther (2005) 22:365-72. doi:10.1111/j.1365-2036.2005.02624.x.
48. Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol (2005) 39:385-9. doi:10.1097/01.mcg.0000159217.47419.5b.
49. Morais MB, Jacob CM. The role of probiotics and prebiotics in pediatric practice. J Pediatr (Rio J) (2006) 82:S189-97. doi:10.2223/JPED.1559.
50. Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr (2008) 62:299-301. doi:10.1038/sj.ejcn.1602718.
51. Savard P, Lamarche B, Paradis ME, Thiboutot H, Laurin E, Roy D. Impact of Bifidobacterium animalis subsp. lactis BB-12 and, Lactobacillus acidophilus LA-5-containing yoghurt, on fecal bacterial counts of healthy adults. Int J Food Microbiol (2011) 149:50-7. doi:10.1016/j.ijfoodmicro.2010.12.026.
52. Taipale T, Pienihakkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr (2011) 105:409-16. doi:10.1017/S0007114510003685.
53. Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther (2012) 12:395-410. doi:10.1517/14712598.2012.664129.
54. Holscher HD, Czerkies LA, Cekola P, Litov R, Benbow M, Santema S, et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr (2012) 36:106S-17S. doi:10.1177/014860711143081736/1_suppl/106S.
55. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr (2000) 30:54-60. doi:10.1097/00005176-200001000-00018.
56. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ (2007) 335:340. doi:10.1136/bmj.39272.581736.55.
57. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children-updated analysis of randomised controlled trials. Aliment Pharmacol Ther (2013) 38(5):467-76. doi:10.1111/apt.12403.
58. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr (1999) 135:564-8. doi:10.1016/S0022-3476(99)70053-3.
59. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther (2011) 33:1302-10. doi:10.1111/j.1365-2036.2011.04665.x.
60. Piescik-Lech M, Urbanska M, Szajewska H. Lactobacillus GG (LGG) and smectite versus LGG alone for acute gastroenteritis: a double-blind, randomized controlled trial. Eur J Pediatr (2013) 172:247-53. doi:10.1007/s00431-012-1878-2.
61. Hatakka K, Savilahti E, Ponka A, Meurman JH, Poussa T, Nase L, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ (2001) 322:1327. doi:10.1136/bmj.322.7298.1327.
62. Hojsak I, Snovak N, Abdovic S, Szajewska H, Misak Z, Kolacek S. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr (2010) 29:312-6. doi:10.1016/j.clnu.2009.09.008.
63. Liu S, Hu P, Du X, Zhou T, Pei X. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatr (2013) 50:377-81. doi:10.1007/s13312-013-0123-z.
64. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet (2001) 357:1076-9. doi:10.1016/S0140-6736(00)04259-8.
65. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol (2007) 119:1019-21. doi:10.1016/j.jaci.2006.12.608.
66. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, et al. Bacillus clausii therapy to reduce side-effects of anti-helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther (2004) 20:1181-8. doi:10.1111/j.1365-2036.2004.02274.x.
67. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother (2011) 45:960-6. doi:10.1345/aph.1Q104.
68. Marseglia GL, Tosca M, Cirillo I, Licari A, Leone M, Marseglia A, et al. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag (2007) 3:13-7. doi:10.2147/tcrm.2007.3.1.13.
69. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther (2007) 25:257-64. doi:10.1111/j.1365-2036.2006.03202.x.
70. Piescik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther (2013) 37:289-303. doi:10.1111/apt.12163.
71. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol (2006) 101:812-22. doi:10.1111/j.1572-0241.2006.00465.x.
72. Segarra-Newnham M. Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother (2007) 41:1212-21. doi:10.1345/aph.1K110.
73. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr (2006) 149:367-72. doi:10.1016/j.jpeds.2006.04.053.
74. Doron SI, Hibberd PL, Gorbach SL. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol (2008) 42(Suppl 2):S58-63. doi:10.1097/MCG.0b013e3181618ab7.
75. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev (2011) 11:CD004827. doi:10.1002/14651858.CD004827.pub3.
76. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol (2010) 16:2202-22. doi:10.3748/wjg.v16.i18.2202.
77. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci (2000) 45:1462-4. doi:10.1023/A:1005588911207.
78. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol (2003) 15:697-8. doi:10.1097/01.meg.0000059138.68845.06.
79. Guslandi M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol (2010) 44:385. doi:10.1097/MCG.0b013e3181cb4233.
80. Saint-Marc T, Rossello-Prats L, Touraine JL. [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS]. Ann Med Interne (Paris) (1991) 142:64-5.
81. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 97:2744-9. doi:10.1111/j.1572-0241.2002.07063.x.
82. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther (2010) 32:1069-79. doi:10.1111/j.1365-2036.2010.04457.x.
83. Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int (2003) 45:86-90. doi:10.1046/j.1442-200X.2003.01671.x.
84. Shimbo I, Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, et al. Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. World J Gastroenterol (2005) 11:7520-4.
85. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 53:1617-23. doi:10.1136/gut.2003.037747.
86. Henker J, Muller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol (2008) 46:874-5. doi:10.1055/s-2008-1027463.
87. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med (2010) 10:13. doi:10.1186/1472-6882-10-13.
88. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr (2007) 166:311-8. doi:10.1007/s00431-007-0419-x.
89. Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J (2008) 27:494-9. doi:10.1097/INF.0b013e318169034c.
90. Mollenbrink M, Bruckschen E. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Med Klin (Munich) (1994) 89:587-93.
91. Plassmann D, Schulte-Witte H. [Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey]. Med Klin (Munich) (2007) 102:888-92. doi:10.1007/s00063-007-1116-2.
92. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis (2012) 27:467-74. doi:10.1007/s00384-011-1363-9.
93. Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs (2006) 66:1371-87. doi:10.2165/00003495-200666100-00006.
94. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs (2012) 72:803-23. doi:10.2165/11632710-000000000-000003.
95. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev (2010) 6:CD001176. doi:10.1002/14651858.CD001176.pub2.
96. Wall GC, Schirmer LL, Anliker LE, Tigges AE. Pharmacotherapy for acute pouchitis. Ann Pharmacother (2011) 45:1127-37. doi:10.1345/aph.1P790.
97. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol (2006) 40:264-9. doi:10.1097/00004836-200603000-00020.
98. Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res (2008) 64:418-22. doi:10.1203/PDR.0b013e318181b7fa.
99. Wang Z, Wang J, Cheng Y, Liu X, Huang Y. Secreted factors from Bifidobacterium animalis subsp. lactis inhibit NF-kappaB-mediated interleukin-8 gene expression in Caco-2 cells. Appl Environ Microbiol (2011) 77:8171-4. doi:10.1128/AEM.06145-11AEM.06145-11.
100. Ruiz PA, Hoffmann M, Szcesny S, Blaut M, Haller D. Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology (2005) 115:441-50. doi:10.1111/j.1365-2567.2005.02176.x.
101. Mohan R, Koebnick C, Schildt J, Schmidt S, Mueller M, Possner M, et al. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol (2006) 44:4025-31. doi:10.1128/JCM.00767-06.
102. Khailova L, Frank DN, Dominguez JA, Wischmeyer PE. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anesthesiology (2013) 119:166-77. doi:10.1097/ALN.0b013e318291c2fc.
103. Giahi L, Aumueller E, Elmadfa I, Haslberger AG. Regulation of TLR4, p38 MAPkinase, IkappaB and miRNAs by inactivated strains of lactobacilli in human dendritic cells. Benef Microbes (2012) 3:91-8. doi:10.3920/BM2011.0052.
104. Kim SW, Park KY, Kim B, Kim E, Hyun CK. Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production. Biochem Biophys Res Commun (2013) 431:258-63. doi:10.1016/j.bbrc.2012.12.121.
105. Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest (2011) 121:2242-53. doi:10.1172/JCI4403144031.
106. Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ, et al. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med (2009) 47:1205-11. doi:10.1016/j.freeradbiomed.2009.07.033.
107. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC-and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol (2008) 294:G1060-9. doi:10.1152/ajpgi.00202.2007.
108. Ciprandi G, Vizzaccaro A, Cirillo I, Tosca MA. Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study. Eur Ann Allergy Clin Immunol (2005) 37:129-34.
109. Gabrielli M, Lauritano EC, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G, et al. Bacillus clausii as a treatment of small intestinal bacterial overgrowth. Am J Gastroenterol (2009) 104:1327-8. doi:10.1038/ajg.2009.91ajg200991.
110. Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol (2004) 38:S86-90. doi:10.1097/01.mcg.0000128925.06662.69.
111. Castagliuolo I, Riegler MF, Valenick L, Lamont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun (1999) 67:302-7.
112. Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, Lamont JT, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun (2001) 69:2762-5. doi:10.1128/IAI.69.4.2762-2765.2001.
113. Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther (2009) 30:826-33. doi:10.1111/j.1365-2036.2009.04102.x.
114. Buts JP, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci (2006) 51:1485-92. doi:10.1007/s10620-005-9016-x.
115. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology (2006) 131:1812-25. doi:10.1053/j.gastro.2006.10.001.
116. Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol (2009) 156:78-87. doi:10.1111/j.1365-2249.2009.03878.x.
117. Rodrigues AC, Cara DC, Fretez SH, Cunha FQ, Vieira EC, Nicoli JR, et al. Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol (2000) 89:404-14. doi:10.1046/j.1365-2672.2000.01128.x.
118. Martins FS, Silva AA, Vieira AT, Barbosa FH, Arantes RM, Teixeira MM, et al. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol (2009) 191:623-30. doi:10.1007/s00203-009-0491-x.
119. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res (1986) 20:192-6. doi:10.1203/00006450-198602000-00020.
120. Brandao RL, Castro IM, Bambirra EA, Amaral SC, Fietto LG, Tropia MJ, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol (1998) 64:564-8.
121. Gedek BR. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses (1999) 42:261-4. doi:10.1046/j.1439-0507.1999.00449.x.
122. Martins FS, Vieira AT, Elian SD, Arantes RM, Tiago FC, Sousa LP, et al. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes Infect (2013) 15:270-9. doi:10.1016/j.micinf.2012.12.007.
123. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O'Brien M, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem (2006) 281:24449-54. doi:10.1074/jbc.M605200200.
124. Martins FS, Dalmasso G, Arantes RM, Doye A, Lemichez E, Lagadec P, et al. Interaction of Saccharomyces boulardii with Salmonella enterica serovar typhimurium protects mice and modifies T84 cell response to the infection. PLoS One (2010) 5:e8925. doi:10.1371/journal.pone.0008925.
125. Wu X, Vallance BA, Boyer L, Bergstrom KS, Walker J, Madsen K, et al. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol (2008) 294:G295-306. doi:10.1152/ajpgi.00173.2007.
126. Pontier-Bres R, Prodon F, Munro P, Rampal P, Lemichez E, Peyron JF, et al. Modification of Salmonella typhimurium motility by the probiotic yeast strain Saccharomyces boulardii. PLoS One (2012) 7:e33796. doi:10.1371/journal.pone.0033796.
127. Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, et al. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr (2011) 50:261-9. doi:10.1007/s00394-010-0134-7.
128. Imase K, Takahashi M, Tanaka A, Tokunaga K, Sugano H, Tanaka M, et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol (2008) 52:156-61. doi:10.1111/j.1348-0421.2008.00026.x.
129. Woo TD, Oka K, Takahashi M, Hojo F, Osaki T, Hanawa T, et al. Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med Microbiol (2011) 60:1617-25. doi:10.1099/jmm.0.033423-0.
130. Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol (2004) 41:219-26. doi:10.1016/j.femsim.2004.03.010.
131. Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, et al. A Single Strain of Clostridium butyricum Induces Intestinal IL-10-Producing Macrophages to Suppress Acute Experimental Colitis in Mice. Cell Host Microbe (2013) 13:711-22. doi:10.1016/j.chom.2013.05.013.
132. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis (2008) 14:1012-8. doi:10.1002/ibd.20377.
133. Troge A, Scheppach W, Schroeder BO, Rund SA, Heuner K, Wehkamp J, et al. More than a marine propeller-the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. Int J Med Microbiol (2012) 302:304-14. doi:10.1016/j.ijmm.2012.09.004.
134. Schierack P, Kleta S, Tedin K, Babila JT, Oswald S, Oelschlaeger TA, et al. E. coli Nissle 1917 affects Salmonella adhesion to porcine intestinal epithelial cells. PLoS One (2011) 6:e14712. doi:10.1371/journal.pone.0014712.
135. Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol (2004) 40:223-9. doi:10.1016/S0928-8244(03)00368-7.
136. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol (2007) 9:804-16. doi:10.1111/j.1462-5822.2006.00836.x.
137. Dai C, Zheng CQ, Meng FJ, Zhou Z, Sang LX, Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-kappaB pathway in rat model of DSS-induced colitis. Mol Cell Biochem (2013) 374:1-11. doi:10.1007/s11010-012-1488-3.
138. Soo I, Madsen KL, Tejpar Q, Sydora BC, Sherbaniuk R, Cinque B, et al. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol (2008) 22:237-42.
139. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol (2009) 296:G1140-9. doi:10.1152/ajpgi.90534.2008.
140. Dai C, Zhao DH, Jiang M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med (2012) 29:202-8. doi:10.3892/ijmm.2011.839.
141. Dharmani P, De Simone C, Chadee K. The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor. PLoS One (2013) 8:e58671. doi:10.1371/journal.pone.0058671.
142. Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis (2011) 17:289-97. doi:10.1002/ibd.21366.
143. Vitali B, Ndagijimana M, Maccaferri S, Biagi E, Guerzoni ME, Brigidi P. An in vitro evaluation of the effect of probiotics and prebiotics on the metabolic profile of human microbiota. Anaerobe (2012) 18:386-91. doi:10.1016/j.anaerobe.2012.04.014.
144. Schiavi E, Barletta B, Butteroni C, Corinti S, Boirivant M, Di Felice G. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. Allergy (2011) 66:499-508. doi:10.1111/j.1398-9995.2010.02501.x.
145. Thang CL, Boye JI, Zhao X. Low doses of allergen and probiotic supplementation separately or in combination alleviate allergic reactions to cow beta-lactoglobulin in mice. J Nutr (2013) 143:136-41. doi:10.3945/jn.112.169466.
146. Madsen KL. The use of probiotics in gastrointestinal disease. Can J Gastroenterol (2001) 15:817-22.
147. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 100:1539-46. doi:10.1111/j.1572-0241.2005.41794.x.
148. Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hormannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes (2010) 1:164-85. doi:10.4161/gmic.1.3.12127.
149. Fukuda S, Toh H, Taylor TD, Ohno H, Hattori M. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes (2012) 3:449-54. doi:10.4161/gmic.21214.
150. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature (2011) 469:543-7. doi:10.1038/nature.
151. Martins FS, Rodrigues AC, Tiago FC, Penna FJ, Rosa CA, Arantes RM, et al. Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype typhimurium and stimulates the immune system in gnotobiotic and conventional mice. J Med Microbiol (2007) 56:352-9. doi:10.1099/jmm.0.46525-0.
152. Martins FS, Elian SD, Vieira AT, Tiago FC, Martins AK, Silva FC, et al. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. Int J Med Microbiol (2011) 301:359-64. doi:10.1016/j.ijmm.2010.11.002.
153. Martins AK, Martins FS, Gomes DA, Elian SD, Vieira AT, Teixeira MM, et al. Evaluation of in vitro antagonism and of in vivo immune modulation and protection against pathogenic experimental challenge of two probiotic strains of Bifidobacterium animalis var. lactis. Arch Microbiol (2010) 192:995-1003. doi:10.1007/s00203-010-0626-0.
154. Tiago FC, Martins FS, Souza EL, Pimenta PF, Araujo HR, Castro IM, et al. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J Med Microbiol (2012) 61:1194-207. doi:10.1099/jmm.0.042283-0.
155. Theodorakopoulou M, Perros E, Giamarellos-Bourboulis EJ, Dimopoulos G. Controversies in the management of the critically ill: the role of probiotics. Int J Antimicrob Agents (2013) 42(Suppl):S41-4. doi:10.1016/j.ijantimicag.2013.04.010.
156. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev (2004) 17:259-75. doi:10.1079/NRR200479.
157. Gloux K, Berteau O, El Oumami H, Beguet F, Leclerc M, Dore J. A metagenomic beta-glucuronidase uncovers a core adaptive function of the human intestinal microbiome. Proc Natl Acad Sci U S A (2011) 108(Suppl 1):4539-46. doi:10.1073/pnas.10000661071000066107.
158. McNeil NI, Cummings JH, James WP. Short chain fatty acid absorption by the human large intestine. Gut (1978) 19:819-22. doi:10.1136/gut.19.9.819.
159. Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res (2013) 69:52-60. doi:10.1016/j.phrs.2012.10.020.
160. Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci U S A (2009) 106:5859-64. doi:10.1073/pnas.0901529106.
161. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature (2011) 473:174-80. doi:10.1038/nature09944.
162. Emilia H, Viktoria S, Jana S, Gabriela H. Chemopreventive and metabolic effects of inulin in colon cancer development. J Vet Sci (2013).
163. Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol (2008) 104:305-44. doi:10.1111/j.1365-2672.2007.03520.x.
164. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr (2009) 101:541-50. doi:10.1017/S0007114508019880.
165. Hopping BN, Erber E, Grandinetti A, Verheus M, Kolonel LN, Maskarinec G. Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii. J Nutr (2010) 140:68-74. doi:10.3945/jn.109.112441.
166. Costabile A, Kolida S, Klinder A, Gietl E, Bauerlein M, Frohberg C, et al. A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) in healthy human subjects. Br J Nutr (2010) 104:1007-17. doi:10.1017/S0007114510001571.
167. Ramnani P, Gaudier E, Bingham M, van Bruggen P, Tuohy KM, Gibson GR. Prebiotic effect of fruit and vegetable shots containing Jerusalem artichoke inulin: a human intervention study. Br J Nutr (2010) 104:233-40. doi:10.1017/S000711451000036X.
168. Scholtens PA, Alles MS, Bindels JG, van der Linde EG, Tolboom JJ, Knol J. Bifidogenic effects of solid weaning foods with added prebiotic oligosaccharides: a randomised controlled clinical trial. J Pediatr Gastroenterol Nutr (2006) 42:553-9. doi:10.1097/01.mpg.0000221887.28877.c7.
169. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut (2011) 60:923-9. doi:10.1136/gut.2010.232025gut.
170. de Luis DA, de la Fuente B, Izaola O, Conde R, Gutierrez S, Morillo M, et al. Double blind randomized clinical trial controlled by placebo with an alpha linoleic acid and prebiotic enriched cookie on risk cardiovascular factor in obese patients. Nutr Hosp (2011) 26:827-33. doi:10.1590/S0212-16112011000400024.
171. Cummings JH, Christie S, Cole TJ. A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. Aliment Pharmacol Ther (2001) 15:1139-45. doi:10.1046/j.1365-2036.2001.01043.x.
172. Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr (2008) 138:1091-5.
173. Boutron-Ruault MC, Marteau P, Lavergne-Slove A, Myara A, Gerhardt MF, Franchisseur C, et al. Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. Nutr Cancer (2005) 53:160-8. doi:10.1207/s15327914nc5302_5.
174. Saavedra JM, Tschernia A. Human studies with probiotics and prebiotics: clinical implications. Br J Nutr (2002) 87(Suppl 2):S241-6. doi:10.1079/BJNBJN/2002543.
175. Drakoularakou A, Tzortzis G, Rastall RA, Gibson GR. A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. Eur J Clin Nutr (2010) 64:146-52. doi:10.1038/ejcn.2009.120.
176. Peng X, Li S, Luo J, Wu X, Liu L. Effects of dietary fibers and their mixtures on short chain fatty acids and microbiota in mice guts. Food Funct (2013) 4:932-8. doi:10.1039/c3fo60052a.
177. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients (2013) 5:1417-35. doi:10.3390/nu5041417.
178. Chen H, Mao X, He J, Yu B, Huang Z, Yu J, et al. Dietary fibre affects intestinal mucosal barrier function and regulates intestinal bacteria in weaning piglets. Br J Nutr (2013) 110:1837-48. doi:10.1017/S0007114513001293.
179. Hu GX, Chen GR, Xu H, Ge RS, Lin J. Activation of the AMP activated protein kinase by short-chain fatty acids is the main mechanism underlying the beneficial effect of a high fiber diet on the metabolic syndrome. Med Hypotheses (2010) 74:123-6. doi:10.1016/j.mehy.2009.07.022.
180. Cao Y, Gao X, Zhang W, Zhang G, Nguyen AK, Liu X, et al. Dietary fiber enhances TGF-beta signaling and growth inhibition in the gut. Am J Physiol Gastrointest Liver Physiol (2011) 301:G156-64. doi:10.1152/ajpgi.00362.
181. Slavin JL. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc (2008) 108:1716-31. doi:10.1016/j.jada.2008.08.007.
182. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 104:13780-5. doi:10.1073/pnas.0706625104.
183. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature (2009) 461:1282-6. doi:10.1038/nature08530.
184. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, De Bruine A, et al. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr (2010) 29:738-44. doi:10.1016/j.clnu.2010.04.002.
185. Huda-Faujan N, Abdulamir AS, Fatimah AB, Anas OM, Shuhaimi M, Yazid AM, et al. The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J (2010) 4:53-8. doi:10.2174/1874091X01004010053.
186. Gibson PR, Rosella O, Wilson AJ, Mariadason JM, Rickard K, Byron K, et al. Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis (1999) 20:539-44. doi:10.1093/carcin/20.4.539.
187. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci (2012) 57:3126-35. doi:10.1007/s10620-012-2259-4.
188. Ritzhaupt A, Wood IS, Ellis A, Hosie KB, Shirazi-Beechey SP. Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J Physiol (1998) 513(Pt 3):719-32. doi:10.1111/j.1469-7793.1998.719ba.x.
189. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr (2003) 133:2485S-93S.
190. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res (2003) 1:855-62.
191. Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Boxberge F, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol (2002) 37:458-66. doi:10.1080/003655202317316105.
192. Schwab M, Reynders V, Ulrich S, Zahn N, Stein J, Schroder O. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis (2006) 11:1801-11. doi:10.1007/s10495-006-9788-2.
193. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest (1999) 104:383-9. doi:10.1172/JCI7145.
194. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology (2013) 145:396-406. doi:10.1053/j.gastro.2013.04.056S0016-5085(13)00708-7.
195. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (2013) 341(6145):569-73. doi:10.1126/science.1241165.
196. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2003) 278:11312-9. doi:10.1074/jbc.M211609200.
197. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr (1995) 125:1401-12.
198. Aslam MN, Bergin I, Naik M, Paruchuri T, Hampton A, Rehman M, et al. A multimineral natural product from red marine algae reduces colon polyp formation in C57BL/6 mice. Nutr Cancer (2012) 64:1020-8. doi:10.1080/01635581.2012.713160.